AssayIndex
Incretin analogues and co-agonists

Pemvidutide

ALT-801 · GLP-1/glucagon dual agonist · C218H336N48O66 · monoisotopic 4679.4014 Da. The index holds 35 assay reports on this compound across 5 batches from 5 suppliers.

35 reports5 batchesmedian 98.41 %index spec 96.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Pemvidutide is thinly covered — fewer than 40 reports index-wide — and the index publishes its statistics only with an explicit low-n badge. Retention is late (20.4 min) and the EASE lipid tail makes it the most hydrophobic compound routinely submitted here; labs running a 45 % B end-point will not elute it at all, which accounts for two of the three "no peak detected" records on file. Where a submitter reports no peak, the index records the method rather than the material as the finding.

Molecular formula
C218H336N48O66
Monoisotopic mass
4679.4014Da
Average mass
4682.20Da
Residues
39
Nominal retention (RG-2, 30 min)
20.36min
Retention window
0.50min
Counter-ion as usually shipped
TFA
Typical label claims
1.2 mg · 1.8 mg · 2.4 mg
Analytical difficulty (index scale)
1.45 — hard
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

01306261239175223 Pemvidutide20.36 min · 98.41 % 18.8120.94 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Pemvidutide trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 98.41 % area at the nominal retention time of 20.36 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 35 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 98.41% n=35
Interquartile range 0.78pp n=35
Minimum 96.91% n=35
Maximum 99.93% n=35
Pass rate vs spec 100.0% n=35
Median recovery vs claim 96.9% n=16
Median water 4.74% n=35
Median |mass error| 2.9ppm n=31
024692.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=197.00–97.25 %: n=097.25–97.50 %: n=397.50–97.75 %: n=397.75–98.00 %: n=498.00–98.25 %: n=398.25–98.50 %: n=598.50–98.75 %: n=798.75–99.00 %: n=499.00–99.25 %: n=399.25–99.50 %: n=199.50–99.75 %: n=099.75–100.00 %: n=1median 98.41 Purity (% area) Reports
Figure 2. Purity distribution across all 35 Pemvidutide records. Dashed line is this compound's median (98.41 %); the solid vertical is the index acceptance specification for the incretin analogues and co-agonists class (96.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.197.698.198.699.199.6100.1BCHBCH: Q1 97.55, median 97.98, Q3 98.35, n=12n=12QYBQYB: Q1 98.52, median 98.93, Q3 99.08, n=9outlier 97.31n=9CPCCPC: Q1 98.11, median 98.35, Q3 98.55, n=8n=8ERPERP: Q1 98.68, median 98.78, Q3 98.85, n=5outlier 98.42outlier 99.93n=5 Purity (% area)
Figure 3. Pemvidutide purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-EDA linker (−60 Da)-0.88-60.048100%0.241.27
truncated (3-39)-1.55-222.112100%0.651.61
[D-Aib2]-diastereomer-0.20mass-identical97%0.461.17
aspartimide (−18 Da)+0.58-18.01197%0.181.37

Degradation pathways

  • aspartimide formation
  • lipid-tail hydrolysis

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Pemvidutide phase 2 obesity and MASH data were presented in 2024; no approved product exists.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q30n<3—
2024-Q40n<3—
2025-Q1698.7396.91–99.93
2025-Q20n<3—
2025-Q32198.3497.31–99.29
2025-Q4898.3597.85–98.81
2026-Q10n<3—
2026-Q20n<3—
2026-Q30n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Pemvidutide records of 35.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-020916CPCCPC-2507-H2201Medutest2025-Q498.663.85—Supplier-supplied3MARGINAL
AX-2025-020914CPCCPC-2507-H2201Kestrel2025-Q498.414.3596.8Buyer-sourced3MARGINAL
AX-2025-020920CPCCPC-2507-H2201PeptideMeter2025-Q498.814.4397.0Supplier-supplied3MARGINAL
AX-2025-020918CPCCPC-2507-H2201Janoshik2025-Q498.173.53103.8Supplier-supplied3MARGINAL
AX-2025-020917CPCCPC-2507-H2201PeptideMeter2025-Q498.293.78—Supplier-supplied3MARGINAL
AX-2025-020919CPCCPC-2507-H2201VendorInvestigate2025-Q497.854.31102.6Buyer-sourced4MARGINAL
AX-2025-020913CPCCPC-2507-H2201Janoshik2025-Q497.934.0290.7Buyer-sourced3MARGINAL
AX-2025-020915CPCCPC-2507-H2201Nordanalyt2025-Q498.513.52—Supplier-supplied3MARGINAL
AX-2025-018613QYBQYB-2502-V5083Nordanalyt2025-Q398.104.15—Supplier-supplied3MARGINAL
AX-2025-018614QYBQYB-2502-V5083Janoshik2025-Q398.523.8596.7Supplier-supplied3MARGINAL
AX-2025-021264BCHBCH-2506-G6608Medutest2025-Q397.485.15—Supplier-supplied2MARGINAL
AX-2025-021260BCHBCH-2506-G6608Janoshik2025-Q398.375.4893.0Supplier-supplied3MARGINAL
AX-2025-018611QYBQYB-2502-V5083Janoshik2025-Q399.293.7394.5Supplier-supplied3MARGINAL
AX-2025-021270BCHBCH-2506-G6608Janoshik2025-Q397.565.97—Supplier-supplied2MARGINAL
AX-2025-021268BCHBCH-2506-G6608PeptideMeter2025-Q398.005.88—Supplier-supplied2MARGINAL
AX-2025-021265BCHBCH-2506-G6608Janoshik2025-Q397.535.58—Buyer-sourced2MARGINAL
AX-2025-018617QYBQYB-2502-V5083Janoshik2025-Q399.013.7794.5Supplier-supplied4FAIL
AX-2025-021267BCHBCH-2506-G6608PeptideMeter2025-Q397.425.57—Supplier-supplied2MARGINAL
AX-2025-018616QYBQYB-2502-V5083Kestrel2025-Q399.084.27—Supplier-supplied3MARGINAL
AX-2025-021266BCHBCH-2506-G6608Janoshik2025-Q398.505.20—Supplier-supplied2MARGINAL
AX-2025-021263BCHBCH-2506-G6608Janoshik2025-Q398.345.2992.2Supplier-supplied2MARGINAL
AX-2025-018610QYBQYB-2502-V5083Janoshik2025-Q399.113.81—Supplier-supplied3MARGINAL
AX-2025-021269BCHBCH-2506-G6608Medutest2025-Q397.636.04107.2Buyer-sourced2MARGINAL
AX-2025-021271BCHBCH-2506-G6608Janoshik2025-Q397.996.33—Laboratory-retained3MARGINAL
AX-2025-018618QYBQYB-2502-V5083VendorInvestigate2025-Q397.313.7189.3Buyer-sourced3MARGINAL